Clinical Trials Browser

Phase 3 × dalpiciclib × Clear all

NCT07467330 2026-03-12

Dalpiciclib Combined With Endocrine Therapy and Metronomic Capecitabine vs Dalpiciclib Combined With Endocrine Therapy for First-line Treatment

Phase 3 Recruiting

Breast Neoplasms

NCT07207070 2025-12-30

A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer.

Phase 3 Recruiting

Breast Neoplasms